Clinical Trials Logo

Metastatic Malignant Neoplasm clinical trials

View clinical trials related to Metastatic Malignant Neoplasm.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02774291 Terminated - Clinical trials for Metastatic Malignant Neoplasm in the Brain

Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes

Start date: April 20, 2017
Phase: Early Phase 1
Study type: Interventional

This pilot clinical trial studies the side effects of anti-ESO (cancer/test antigen) murine T-cell receptor (mTCR)-transduced autologous peripheral blood lymphocytes and combination chemotherapy with cyclophosphamide and fludarabine phosphate in treating patients with cancer that has spread to other places in the body (metastatic) and expresses the gene NY-ESO-1. Donor white blood cells that are treated in the laboratory with anti-cluster of differentiation (CD)3 may help treat metastatic cancer. Drugs used in chemotherapy, such as cyclophosphamide and fludarabine phosphate, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Aldesleukin may stimulate white blood cells, including natural killer cells, to kill metastatic cancer cells. Giving anti-ESO (cancer/test antigen) mTCR-transduced autologous peripheral blood lymphocytes together with combination chemotherapy and aldesleukin may kill more cancer cells.

NCT ID: NCT01664273 Terminated - Clinical trials for Metastatic Malignant Neoplasm

Gene Electrotransfer to Muscle With Plasmid AMEP in Patients With Disseminated Cancer

Start date: July 2012
Phase: Phase 1
Study type: Interventional

Gene transfer by electroporation (gene electrotransfer) uses short electric pulses to transiently permeabilise the cell membrane enabling passage of plasmid DNA into the cell cytosol. It is an efficient non-viral method for gene delivery to various tissues. In this phase I dose-escalating study, patients will be treated with intramuscular gene electrotransfer of plasmid AMEP. Plasmid AMEP encodes protein AMEP which bind to α5β1 og αvβ3 integrins. Primary end point of the trial is safety and secondary end points are efficacy, pharmacokinetics and evaluation of potential discomfort associated with the treatment procedure using VAS (Visual Analogue Scale).